All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Epcoritamab for patients with R/R FL: Results from EPCORE NHL-1 trial
|
The ongoing phase I/II EPCORE NHL-1 trial (NCT03625037) is evaluating the safety and efficacy of epcoritamab, a subcutaneous CD3×CD20 bispecific antibody, in patients with relapsed/refractory (R/R) B-cell lymphoma.1 Results from this trial were reported previously by the Lymphoma Hub. Part 2 of the EPCORE NHL-1 trial includes a cohort of 128 adult patients with follicular lymphoma (FL) with ≥2 prior lines of therapy.1 Primary results from this cohort were published in Lancet Hematology by Linton, et al.1 Results from this trial led to the approval of epcoritamab for patients with R/R FL with ≥2 prior lines of therapy by the U.S. Food and Drug Administration (FDA), as well as issue of a positive opinion for the treatment of this population from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). |
| Key learnings: |
|
Epcoritamab demonstrated a significant overall response rate of 82.0% and a complete response rate of 62.5%, with responses observed in all prespecified subgroups, including in patients with high-risk features. |
|
The safety profile of epcoritamab was manageable and consistent with that previously observed with epcoritamab for the treatment of a cohort of patients with diffuse large B-cell lymphoma. |
|
Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were manageable, with mostly low-grade events, and were further reduced in the Cycle 1 optimization cohort (n = 86), with similar or favorable incidences and severity compared to CAR T-cell therapies. |
|
These findings indicate that epcoritamab is an efficacious treatment option for patients with R/R FL, including those with high-risk disease features. Cycle 1 optimization is important to improve the safety profile of epcoritamab and can facilitate removal of mandatory hospitalization. |
- Linton KM, Vitolo U, Jurczak W, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study. Lancet Hematol. 2024;11(8):e593-e605. DOI: 10.1016/S2352-3026(24)00166-2
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
16 votes - 19 days left ...
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox